Tenet

Q3'11

Earnings Call

November 1, 2011

Forward-Looking Statements

Certain statements contained in this presentation constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements are based on management's current expectations and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from those expressed or implied by such forward-looking statements. Such factors include, among others, the following: the passage of heath care reform legislation and the enactment of additional federal and state health care reform; other changes in federal, state, or local laws and regulations affecting the health care industry; general economic and business conditions, both nationally and regionally; demographic changes; changes in, or the failure to comply with, laws and governmental regulations; the ability to enter into managed care provider arrangements on acceptable terms; changes in Medicare and Medicaid payments or reimbursement; liability and other claims asserted against the Company; competition, including the Company's ability to attract patients to its hospitals; technological and pharmaceutical improvements that increase the cost of providing, or reduce the demand for, health care; changes in business strategy or development plans; the ability to attract and retain qualified personnel, including physicians, nurses and other health care professionals, and the impact on the Company's labor expenses resulting from a shortage of nurses or other health care professionals; the significant indebtedness of the Company; the Company's ability to integrate new businesses with its existing operations; the availability and terms of capital to fund the expansion of the Company's business, including the acquisition of additional facilities; the creditworthiness of counterparties to the Company's business transactions; adverse fluctuations in interest rates and other risks related to interest rate swaps or any other hedging activities the Company undertakes; the ability to continue to expand and realize earnings contributions from the Company's Conifer revenue cycle management and patient communication businesses; and its ability to identify and execute on measures designed to save or control costs or streamline operations. Certain additional risks and uncertainties are discussed in the Company's filings with the Securities and Exchange Commission, including the Company's annual report on Form 10-K and quarterly reports on Form 10-Q. The Company specifically disclaims any obligation to update any forward-looking statement, whether as a result of changes in underlying factors, new information, future events or otherwise.

Non-GAAP Information

This presentation includes certain financial measures such as Adjusted EBITDA, which are not calculated in accordance with generally accepted accounting principles (GAAP). Management recommends that you focus on the GAAP numbers as the best indicator of financial performance.

These alternative measures are provided only as a supplement to aid in analysis of the Company.

Reconciliation between non-GAAP measures and related GAAP measures can be found in the Company's third quarter earnings release issued on November 1, 2011.

Q4'11 EBITDA Walk Forward from Q3'11

	EBITDA * ($mm)	Comments
Q3'11 Adjusted EBITDA	**195**	
California Provider Fee	26	Net proceeds from program covering Q1'11 and Q2'11
HIT Incentive Payment	15	Medicare and Medicaid incentives for meaningful use
Higher discount rate for valuing projected liabilities	22	$16mm favorable variance to impact in Q3'11 Plus – Potential $6mm lift from current 7 year Treasury rate
Cost Efficiencies	20	As cited in September 12, 2011 press release
Medicare pricing	5	1% increase effective October 1, 2011
Bad debt reduction	12	Favorable impact of expected reduction in AR days
Sub-Total	**100**	
Seasonal volume growth + Resolution of old accounts and commercial and government reimbursement disputes	**≥ 29**	
Total - EBITDA Increment: Q3'11 to Q4'11	**≥ 129**	
Q4'11 Adjusted EBITDA Outlook	**≥ 324**	**Lower end of 2011 Outlook range of $1.175 - 1.275 B**

* Estimated effects on Q4'11 Adjusted EBITDA

2011 Outlook Assumptions

		Outlook
Adjusted EBITDA [1]	($Bil)	1.175 – 1.275
Depreciation and Amortization	($mm)	(400) – (410)
Interest Expense, Net	($mm)	(395) – (375)
Income from continuing operations before income taxes [1]	($mm)	380 – 490
Income tax expense [2]	($mm)	(148) – (191)
Net income from continuing operations [1] [2]	($mm)	232 – 299
Preferred stock dividends	($mm)	(24)
Net income attributable to noncontrolling interests	($mm)	(15) – (10)
Net income attributable to common shareholders	($mm)	193 – 265
Weighted average shares outstanding (in millions)	($mm)	487 – 546 [4]
E.P.S. [1] [3] (continuing operations)	($)	0.40 – 0.53

(1) Excludes impairment and restructuring charges, litigation and investigation costs, net gain (losses) from early extinguishment of debt, and net gain (losses) on sales of investments

(2) Uses tax rate of 39 percent excluding unusual adjustments

(3) The high end of the range includes an additional 59 million shares as our mandatory convertible preferred stock is dilutive at this level of earnings

(4) An additional 59 million shares are included as our mandatory convertible preferred stock is dilutive at this level of earnings and the $24 million of preferred stock dividends are excluded for earnings per share computation purposes

2011 Cash Walk Forward *($mm)*

	Sep YTD	Q4 Low	Q4 High	2011 Low	2011 High
EBITDA Outlook	**851**	**324**	**424**	**1,175**	**1,275**
Add Back: Stock Compensation Charges	17	5	8	22	25
Changes in Cash from Operating Assets and Liabilities	(230)	13	30	(217)	(200)
Interest Payments	(255)	(85)	(95)	(340)	(350)
Net Operating Cash before Taxes, Litigation and Disc. Ops.	**383**	**257**	**367**	**640**	**750**
Income Tax (Payments) Refunds, Net	9	(24)	(29)	(15)	(20)
Payments against reserves for restructuring charges and Litigation Costs	(27)	(13)	(3)	(40)	(30)
Net Cash used in by Operating Activities from Disc. Ops.	(41)	(19)	(9)	(60)	(50)
Net Cash Provided by Operating Activities	**324**	**201**	**326**	**525**	**650**
Capital Expenditures – Continuing Operations	(298)	(177)	(227)	(475)	(525)
Investing Activities including Outpatient Acquisitions & MOB Divestitures	(26)	(54)	(39)	(80)	(65)
Net Financing Activities	(220)	(70)	(85)	(290)	(305)
Net Increase (Decrease) in Cash and Cash Equivalents	(220)	(100)	(25)	(320)	(245)
Cash and Cash Equivalents at Beginning of Period	**405**	**185**		**405**	
Cash and Cash Equivalents at End of Period	**185**	**85**	**160**	**85**	**160**

Health Information Technology

HIT

Clinical systems are critical to physician alignment and integration, reduction of medication errors, standardization of clinical practice and reduction of cost

($ in millions)

	2009	2010	2011	2012	2013	2014	2015	2016
HIT Program Expense[(1)]	$12	$21	$43	$63	$42	$17	$0	$0
Gov't HIT Incentives	$0	$0	$65	$64	$91	$62	$30	$8
EBITDA Impact	**($12)**	**($21)**	**$22**	**$1**	**$49**	**$45**	**$30**	**$8**
HIT Capital Expenditures	$49	$64	$95	$125	$69	$20	–	–
Foundation Systems (# Go-Live)	–	8	12	11	10	8	–	–
CPOE Systems (# Go-Live)	–	–	9	17	15	8	–	–

Penalties avoided by achieving "Meaningful Use" (Net present value of $315mm)

Cumulative positive net impact on EBITDA starting in 2013

1. *Excludes recurring clinical support operating expenses and HIT benefits to operating performance.*

Tenet